# Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

> **NCT02410590** · PHASE4 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** Rocuronium
- **DRUG:** Sugammadex
- **DRUG:** Cisatracurium
- **DRUG:** Neostigmine/Atropine
- **DRUG:** Succinylcholine

## Key facts

- **NCT ID:** NCT02410590
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-07
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02410590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02410590, "Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02410590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*